Our study highlights that the more aggressive TET subtypes, as well as advanced-stage TETs, are characterized by increased PD-L1 expression in neoplastic cells and decreased PD-L1 expression in the immune cells of the TME. The gene discussed is CD274; the disease is thymic epithelial neoplasm.